| 重组改构人肿瘤坏死因子联合治疗非小细胞肺癌的临床疗效 |
| 投稿时间：2017-09-01 修订日期：2017-09-10 点此下载全文 |
| 引用本文：翁小娇,吴日平,高鑫艳,赖金火.重组改构人肿瘤坏死因子联合治疗非小细胞肺癌的临床疗效[J].医学研究杂志,2018,47(5):104-108 |
| DOI：
10.11969/j.issn.1673-548X.2018.05.026 |
| 摘要点击次数: 870 |
| 全文下载次数: 737 |
|
|
| 中文摘要:目的 探讨注射用重组改构人肿瘤坏死因子联合多西他赛加顺铂化疗治疗非小细胞肺癌（NSCLC）的临床效果。方法 选取2013年5月~2016年3月笔者医院收治的178例NSCLC患者，根据就诊顺序随机分为对照组和研究组，每组89例。对照组予多西他赛联合顺铂方案治疗，研究组在上述基础上加用重组改构人肿瘤坏死因子治疗，均以21天为1个疗程，连续治疗4个疗程，并酌情予对症处理。检测血清肿瘤标志物变化，应用中国癌症化疗患者生活质量量表（QLQ-CCC）和卡氏功能状态量表（KPS）评估生活质量，记录毒性不良反应情况和生存情况，并比较临床效果。结果 与治疗前比较，两组血清肿瘤标志物癌胚抗原（CEA）、糖蛋白抗原125（CA125）、细胞角蛋白19片段（Cyfra21-1）水平降低（P<0.01），QLQ-CCC量表躯体、心理、社会评分及总评分均降低（P<0.01），KPS评分升高（P<0.05）；与对照组比较，研究组CEA、CA125、Cyfra21-1水平较低（P<0.01），QLQ-CCC量表躯体、心理、社会评分及总评分均较高（P<0.01），KPS评分较高（P<0.05），客观缓解率（ORR）较高（P<0.05）；截止随访，对照组生存率为35.96%（32/89）低于研究组生存率64.04%（57/89），差异有统计学意义（P<0.05）。结论 注射用重组改构人肿瘤坏死因子联合多西他赛加顺铂治疗非小细胞肺癌疗效显著，有效提高生存率和生活质量，值得临床推广。 |
| 中文关键词:非小细胞肺癌 重组改构人肿瘤坏死因子 多西他赛 顺铂 |
| |
| Clinical Effect of Recombinant Mutant Human Tumor Necrosis Factor on the Treatment of Non-small Cell Lung Cancer |
|
|
| Abstract:Objective To investigate the clinical effect of Recombinant Mutant Human Tumor Necrosis Factor injection combined with docetaxel and cisplatin in the treatment of non-small cell lung cancer.Methods Totally 178 patients with NSCLC in our hospital from May 2013 to March 2016 were randomly divided into the control group and the study group, 89 patients each. The control group was treated with docetaxel combined with cisplatin treatment, and the study group received more with recombinant mutant human tumor necrosis factor injection, 21d for a course, and 2 groups were treated for 4 courses. Levels of serum tumor markers changes, application of Chinese cancer chemotherapy patient quality of life scale (QLQ-CCC) and the Karnofsky performance status scale (KPS) assessment of quality of life were compared, and toxicity and survival rate were recorded, and the clinical effects were compared.Results Compared with before treatment, 2 groups of serum tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and cytokeratin 19 fragment (Cyfra21-1) decreased (P<0.01), QLQ-CCC scale physical, psychological and social score and total scores decreased (P<0.01), KPS scores increased (P<0.05). Compared with the control group, the study group of CEA, CA125 and Cyfra21-1 were lower (P<0.01), levels of QLQ-CCC scale physical, psychological and social scores and total scores were higher (P<0.01), KPS scores were higher (P<0.05), Objective response rate (ORR) was higher (P<0.05). At the cut-off follow-up, the survival rate of the control group35.96% (32/89) was lower than the study group, and the survival rate64.04% (57/89) was lower than the study group(P<0.05).Conclusion Recombinant Mutant Human Tumor Necrosis Factor injection combined with docetaxel and cisplatin in the treatment of non-small cell lung cancer was effective, and it can improve the survival rate and quality of life, which was worthy of promotion. |
| keywords:Non-small cell lung cancer Recombinant human tumor necrosis factor Docetaxel Cisplatin |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
